Citi's $35bn Booking Blunder Exposes Banking's Control Gap
Published on 22 November 2026
Read article
Listen to article
6:31Hey! We are Nemo.
Nemo, short for Never Miss Out, is a mobile investment platform that delivers curated, data-driven investment ideas to your fingertips. It offers commission-free trading across stocks, ETFs, crypto, and CFDs, along with AI-powered tools, real-time market alerts, and themed stock collections called Nemes.
Download the App
Scan the QR code to download the Nemo app and start investing on Nemo today
There are few things in life more certain than the ever-expanding maze of rules and regulations. I’ve always found it fascinating how, for every new rule created, an entire industry seems to pop up to help people navigate it. It’s the circle of life, but for paperwork. And right now, I think we’re seeing a prime example of this unfolding in the colossal, and frankly bewildering, world of American healthcare.
The starting pistol was fired when the US Department of Justice decided to take a long, hard look at UnitedHealth Group, the biggest beast in the healthcare jungle. The investigation is all about billing practices, which sounds dreadfully dull, but the implications are anything but. To me, this isn't just about one company’s potential headache. It’s a signal flare, warning the entire sector that the days of light-touch oversight may be well and truly over.
So, where does an investor look when the regulators start circling? Do you run for the hills? Not necessarily. When governments create complex problems, clever companies pop up to sell the solutions. It’s the classic story of selling shovels in a gold rush, only this time the gold is compliance and the shovels are consulting services and sophisticated software.
Think about it. If a giant like UnitedHealth, with all its resources, is under the microscope, what hope does a smaller hospital or insurer have? They will almost certainly need to call for backup. This is where firms like Huron Consulting Group, specialists in navigating regulatory minefields, could see their phones ringing off the hook. Similarly, companies such as Health Catalyst, which use data analytics to spot compliance issues before they become multi-million dollar fines, suddenly look less like a business expense and more like an essential insurance policy. The demand for their expertise isn't just a possibility, it’s a near certainty in this new climate.
What makes this particularly interesting is that we’re not just talking about hiring more auditors with clipboards. The old way of doing things, with manual checks and periodic reviews, is simply too slow and clumsy for the modern regulatory environment. The real shift is towards technology.
We’re seeing the rise of AI-powered systems that can monitor a company’s operations in real time, flagging potential problems before a human ever would. This is a fundamental change from a reactive, ‘let’s hope we don’t get caught’ approach to a proactive, data-driven one. It suggests that the demand for these services isn’t a temporary blip. As the rules become permanently more complex, the need for these advanced technological solutions could become a permanent fixture of the healthcare industry’s balance sheet.
Of course, one must never get carried away. Investing based on regulatory shifts is an event-driven game, and events are, by their nature, unpredictable. The political winds could change, and the regulatory pressure might ease. It’s a risk you have to acknowledge. Competition will also heat up as more companies try to get a piece of this compliance pie. Success is never guaranteed, and any investment carries the risk of loss. For those intrigued by this complex dance between regulation and profit, one way to explore the companies at the heart of this shift is through thematic baskets, such as the Riding The Regulatory Wave In Healthcare, which group together relevant stocks. But even then, it’s crucial to remember that nothing in investing is a sure bet.
View the full Basket:Riding The Regulatory Wave In Healthcare
View the full Basket:Riding The Regulatory Wave In Healthcare
This article is marketing material and should not be construed as investment advice. No information set out in this article be considered, as advice, recommendation, offer, or a solicitation, to buy or sell any financial product, nor is it financial, investment, or trading advice. Any references to specific financial product or investment strategy are for illustrative / educational purposes only and subject to change without notice. It is the investor’s responsibility to evaluate any prospective investment, assess their own financial situation, and seek independent professional advice. Past performance is not indicative of future results. Please refer to our Risk Disclosure.
Published on 22 November 2026
Read article
Published on 22 November 2026
Read article
Published on 21 November 2026
Read article
Published on 21 November 2026
Read article
Published on 19 November 2026
Read article